Patents (1436 Stem Cell Patents)

Patents

Order by:
<< | < | 1 2 3 4 5 6 | > | >>


Methods for identifying factors for differentiating definitive endoderm

Patent Number: 7,541,185
Continuing its tradition of IP excellence, Novocell took a very interesting angle in the current patent.  Covered are tests for identifying factors that can induce stem cell differentiation into endoderm.The first independent claim is:" A method of identifying a factor that promotes the differentiation of human definitive endoderm cells, said method comprising the steps of: obtaining a...
Inventors: D'Amour; Kevin Allen (San Diego, CA), Agulnick; Alan D. (San Marcos, CA), Eliazer; Susan (San Diego, CA), Baetge; Emmanuel E. (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday December 23rd, 2003

Method of generating human retinal progenitors from embryonic stem cells

Patent Number: 7,541,186
This patent covers the generation of retinal progenitor cells from embryonic stem cells.  Neural stem cells have previously been demonstrated to have ability to differentiate into retinal tissue, as well as embryonic stem cell derived cells.  The current patent covers a methodology involving the generation of embryoid...
Inventors: Reh; Thomas (Seattle, WA), Lamba; Deepak (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday February 22nd, 2006

Method of expanding undifferentiated hemopoietic stem cells

Patent Number: 7,534,609
Expansion of hematopoietic stem cells would, at face value, allow the possibility of curing many hematological diseases by the process of selecting non-leukemic stem cells, ex vivo expanding them, and providing them back to the patient after myeloablation has destroyed the resident malignant cells.Pluristem (Nasdaq:PSTI) is developing adult...
Inventors: Merchav; Shoshana (Haifa, IL), Meretski; Shai (Haifa, IL)
Assignee: Pluristem Life Systems Inc. (Haifa, IL)
Date of First Priority Issue: Thursday February 4th, 1999

Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin

Patent Number: 7,534,765
This patent covers the use of prolactin alone or in combinations with other agents for enhancing formation of oligodendrocytes in vivo.  It is assigned to the company Stem Cell Therapeutics, out of Calgary Canada, who is currently using hCG and EPO for treatment of strokes in Phase II clinical trials.  Other patents owned by Stem Cell Therapeutics include #Inventors: Gregg; Christopher (Cambridge, MA), Weiss; Samuel (Calgary, CA)
Assignee: Stem Cell Therapeutics Inc. (Calgary, Alberta, Canada)
Date of First Priority Issue: Tuesday September 27th, 2005

Growth and differentiation of adult muscle stem cells with activators or inhibitors of Wnt signaling

Patent Number: 7,541,183
Depending on extent of injury, bone marrow derived stem cells are known to mobilize and migrate in order to accelerate healing.  This has been demonstrated in conditions such as heart attack, stroke, and in critical limb ischemia after administration of exogenous stem cells.Various parts of the body...
Inventors: Rudnicki; Michael (Gloucester, CA), Seale; Patrick (Brookline, MA), Polesskaya; Anna (Villejuif, FR), Fortin; Anouk (Gloucester, CA)
Assignee: Ottawa Health Research Institute (Ottawa, Ontario, CA)
Date of First Priority Issue: Wednesday June 25th, 2003

Angiogenically effective unit dose of FGF-2 and method of use

Patent Number: 7,541,333
Stimulation of therapeutic angiogenesis offers great potential, not only for the obvious conditions such as critical limb ischemia and angina, but also for other indications post-stroke recovery and liver failure.  Methods of stimulating angiogenesis range from administration of Inventors: Whitehouse; Martha Jo (San Francisco, CA)
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Date of First Priority Issue: Tuesday October 13th, 1998

Stem cells and their use in transplantation

Patent Number: 7,537,756
The problem with islet transplantation is that one needs 2-3 pancreatic donors per recipient, and even this high number of islets still end up eventually being rejected/nonfunctional.  Additionally the recipient needs to be on immune suppression.  These drawbacks are not only because of allogeneic issues, but also due to poor vascularization once the islets are injected via the hepatic...
Inventors: Habener; Joel E. (Newton Centre, MA), Zulewski; Hendrik (Basel, CH), Abraham; Elizabeth J. (Quincy, MA), Vallejo; Mario (Madrid, ES), Faustman; Denise L. (Weston, MA), Thomas; Melissa K. (Boston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Monday December 6th, 1999

Methods of producing pancreatic hormones

Patent Number: 7,534,608
The company Novocell (merged from Cythera, BresaGen, and Novocell) has been strategically developing an IP portfolio covering numerous aspects of treating diabetes.  Having IP on endoderm, as well as encapsulation technologies, the company recently was issued the current patent covering generation of insulin producing cells from embryonic stem cells.  The...
Inventors: Martinson; Laura (San Diego, CA), Kroon; Evert (San Diego, CA), D'Amour; Kevin (San Diego, CA), Baetge; Emmanuel Edward (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Friday March 2nd, 2007

Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices

Patent Number: 7,531,505
Lack of proper endothelialization of vascular grafts can cause a variety of problems such as restenosis or thrombosis.  The current patent covers a coating for medical devices in which one side of the coating binds to the metallic surface of the device and the other side contains peptides that bind to endothelium or endothelial precursor cells.  This patent...
Inventors: Hamilton; Paul Theodore (Cary, NC), Kenan; Daniel James (Chapel Hill, NC), Solan; Amy Katherine (Durham, NC)
Assignee: Affinergy, Inc. (Durham, NC)
Date of First Priority Issue: Wednesday January 11th, 2006

Double nuclear transfer method and results thereof

Patent Number: 7,531,715
The area of cloning is of great interest in terms of therapeutics development, not only from the perspective of generating de novo stem cell populations, but also the possibility of making transgenic animals for practical purposes such as food or protein production.  Accordingly, numerous patents have been issued on all sorts of variations of the cloning process, as well as...
Inventors: Campbell; Keith H. S. (Leicestershire, GB)
Assignee: PPL Therapeutics (Scotland) (Edinburgh, GB)
Date of First Priority Issue: Wednesday January 13th, 1999

Order by:
<< | < | 1 2 3 4 5 6 | > | >>


Home | News | Patents | Products | Jobs | Links | Search | Journal | RSS

About | Advisory Board | Newsletter | Advertise | Contact | Sitemap | Privacy Policy | Terms of Use

Copyright © 2006 - 2024 StemCellPatents.com - All rights reserved. - Toronto Web Design

StemCellPatents.com V2.04

Stouffville Concrete | Tottenham Concrete | Uxbridge Concrete | Stouffville Real Estate Agent